These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 32205092)

  • 1. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.
    Wu D; Yang XO
    J Microbiol Immunol Infect; 2020 Jun; 53(3):368-370. PubMed ID: 32205092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
    Goker Bagca B; Biray Avci C
    Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer.
    Barbieri A; Robinson N; Palma G; Maurea N; Desiderio V; Botti G
    Front Immunol; 2020; 11():588724. PubMed ID: 33117402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The COVID-19 Cytokine Storm; What We Know So Far.
    Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
    Front Immunol; 2020; 11():1446. PubMed ID: 32612617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine storm intervention in the early stages of COVID-19 pneumonia.
    Sun X; Wang T; Cai D; Hu Z; Chen J; Liao H; Zhi L; Wei H; Zhang Z; Qiu Y; Wang J; Wang A
    Cytokine Growth Factor Rev; 2020 Jun; 53():38-42. PubMed ID: 32360420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
    Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
    Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
    Miao Y; Fan L; Li JY
    Front Immunol; 2020; 11():1445. PubMed ID: 32612616
    [No Abstract]   [Full Text] [Related]  

  • 9. Should we unstress SARS-CoV-2 infected cells?
    Csukasi F; Rico G; Becerra J; Duran I
    Cytokine Growth Factor Rev; 2020 Aug; 54():3-5. PubMed ID: 32563554
    [No Abstract]   [Full Text] [Related]  

  • 10. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.
    Nile SH; Nile A; Qiu J; Li L; Jia X; Kai G
    Cytokine Growth Factor Rev; 2020 Jun; 53():66-70. PubMed ID: 32418715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
    Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
    Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?
    Costiniuk CT; Jenabian MA
    Cytokine Growth Factor Rev; 2020 Jun; 53():63-65. PubMed ID: 32467020
    [No Abstract]   [Full Text] [Related]  

  • 13. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
    La Rosée F; Bremer HC; Gehrke I; Kehr A; Hochhaus A; Birndt S; Fellhauer M; Henkes M; Kumle B; Russo SG; La Rosée P
    Leukemia; 2020 Jul; 34(7):1805-1815. PubMed ID: 32518419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2: An immunogenetics call to arms.
    Clark B; Poulton K
    Int J Immunogenet; 2020 Aug; 47(4):319-323. PubMed ID: 32654378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surviving the storm: Dealing with COVID-19.
    Vandenbark AA; Meza-Romero R; Offner H
    Cell Immunol; 2020 Aug; 354():104153. PubMed ID: 32563849
    [No Abstract]   [Full Text] [Related]  

  • 16. IL-6: Relevance for immunopathology of SARS-CoV-2.
    Gubernatorova EO; Gorshkova EA; Polinova AI; Drutskaya MS
    Cytokine Growth Factor Rev; 2020 Jun; 53():13-24. PubMed ID: 32475759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines and COVID-19: friends or foes?
    Rokni M; Hamblin MR; Rezaei N
    Hum Vaccin Immunother; 2020 Oct; 16(10):2363-2365. PubMed ID: 32841579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab administration in a refractory case of COVID-19.
    Dastan F; Nadji SA; Saffaei A; Tabarsi P
    Int J Antimicrob Agents; 2020 Aug; 56(2):106043. PubMed ID: 32502524
    [No Abstract]   [Full Text] [Related]  

  • 19. SARS-CoV-2 infection-induced immune responses: Friends or foes?
    Li K; Hao Z; Zhao X; Du J; Zhou Y
    Scand J Immunol; 2020 Aug; 92(2):e12895. PubMed ID: 32445403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine Storms: Understanding COVID-19.
    Mangalmurti N; Hunter CA
    Immunity; 2020 Jul; 53(1):19-25. PubMed ID: 32610079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.